Results 31 to 40 of about 6,725 (159)
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan +4 more
wiley +1 more source
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
Medicinal Research Reviews, EarlyView.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo +4 more
wiley +1 more source
Cancer Science, EarlyView.In 5829 Korean patients undergoing hereditary cancer germline testing, 987 (16.9%) carried pathogenic/likely pathogenic variants. Post‐test management varied substantially across gene groups, while variant reclassification identified 46 additional carriers, underscoring the need for gene‐specific management and structured recontact.
Min‐Chae Kang +13 more
wiley +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Real-world TRAE association between niraparib and platinum-based chemotherapy
Frontiers in OncologyBackgroundPre-clinical studies showed the anti-tumor mechanisms of PARP inhibitors (PARPi) and platinum have some crossover and overlap in the DNA damage repair pathway, patients who respond to platinum-based chemotherapy are also more likely to be ...
Linli Wang +4 more
doaj +1 more source
Histopathology, EarlyView.CDK4/6 inhibitor‐induced liver injury represents a clinically significant and histologically distinctive form of drug‐induced hepatotoxicity, most commonly encountered with ribociclib. The predominant pattern is severe acute hepatocellular injury, frequently accompanied by lymphocytic cholangitis, a combination that, in the appropriate clinical context,
Sunayana Misra +4 more
wiley +1 more source
Journal of Cell Communication and Signaling, Volume 20, Issue 4, December 2026.The combined single‐cell and functional analysis depicts that miR‐941 targets CLDN4 and activates the regulatory axis that drives the malignancy of thyroid cancer through the PI3K/AKT pathway. Abstract Claudin‐4 (CLDN4), a key tight junction protein, has been implicated in tumor progression; however, its functional role and regulatory mechanisms in ...
Jinghua Zhou +9 more
wiley +1 more source
MLMP: A Methylation‐Associated lncRNA‐mRNA Prognostic Signature for Endometrial Carcinoma
Cancer Medicine, Volume 15, Issue 11, November 2026.ABSTRACT Background Endometrial carcinoma (EC) is one of the most common gynecological malignancies. Aberrant DNA methylation (DNAm) is an important epigenetic alteration involved in cancer progression. Long non‐coding RNAs (LncRNAs) play critical roles in gene regulation and pathological processes.
Hong Kou +10 more
wiley +1 more source
Molecular CancerOvarian cancer is a gynecological malignancy with the highest recurrence and mortality rates. Although niraparib can effectively affect its progression, the challenge of drug resistance remains.
Bingfeng Lu +10 more
doaj +1 more source